Source: Fierce Biotech Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The acquisition, announced Tuesday, would give Incyte ownership over two budding immunology and inflammation candidates, led by EP262, in development for a handful of inflammatory skin conditions. The second asset,…...